Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874214 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL14690552 | 0.81 | MAPK8 (0.54) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL5010704 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL21767777 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL16076619 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL29416299 | 0.80 | KDM4E (0.70) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL68952 | 0.80 | KDM4E (0.70) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL1440123 | 0.77 | SIRT3 (0.61) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL30957166 | 0.77 | SIRT3 (0.61) | KDM4EALDH1A1GLAGAAMAPK8 | |
| SCHEMBL9700938 | 0.77 | KDM4E (0.61) | KDM4EALDH1A1GLAGAAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912684-B2 | N-(4-pyridyl)nicotinamide compound or salt thereof | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| CN-110573496-B | N- (4-pyridyl) nicotinamide compound or salt thereof | 石原产业株式会社 | 2023-10-24 | — | — | CN | disclosed |
| EP-3617196-B1 | N-(4-PYRIDYL) NICOTINAMIDE COMPOUND OR SALT THEREOF | ISHIHARA SANGYO KAISHA (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20210115015-A1 | N-(4-PYRIDYL)NICOTINAMIDE COMPOUND OR SALT THEREOF | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| EP-3617196-A1 | N-(4-PYRIDYL) NICOTINAMIDE COMPOUND OR SALT THEREOF | Ishihara Sangyo Kaisha, Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573496-A | N- (4-pyridyl) nicotinamide compounds or salts thereof | 石原产业株式会社 | 2019-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115015-A1 | N-(4-PYRIDYL)NICOTINAMIDE COMPOUND OR SALT THEREOF | NAMPT, NAPRT, NNT | KDM4E 808/4885ALDH1A1 1228/4885GLA 2690/4885 |
| US-11912684-B2 | N-(4-pyridyl)nicotinamide compound or salt thereof | NAMPT, NAPRT, NNT | KDM4E 808/4885ALDH1A1 1228/4885GLA 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.